Skip to main content
Premium Trial:

Request an Annual Quote

AmerisourceBergen's ION Solutions Partners With Myriad Genetics on Hereditary Cancer Testing

NEW YORK (GenomeWeb) – Myriad Genetics will be ION Solutions' preferred partner for providing hereditary cancer genetic testing to its member practices, the firms announced today.

ION Solutions is an organization under AmerisourceBergen that provides expertise, technologies, and resources to more than half the community-based oncology practices in the US. Myriad markets MyRisk Hereditary Cancer, a 28-gene panel that assesses whether patients have an increased risk for eight cancers.

"This partnership will advance the organizations' shared goals of providing accurate and comprehensive hereditary cancer test results and service to community oncologists and their patients," ION said in a statement.

In 2014, ION announced a similar preferred partner arrangement with Foundation Medicine in an effort to bring comprehensive genomic profiling services to community oncologists with the FoundationOne and FoundationOne Heme tests. 

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.